Disrupting deep sleep boosts the amount of an Alzheimer’s disease-related protein called amyloid-beta in the fluid bathing the brain and spinal cord, new research suggests.

Merck announced that it has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. Changes in tau are associated with a number of diseases affecting the nervous system, including Alzheimer’s disease (AD).